34,568 AbbVie Inc. $ABBV Shares Acquired by Gimbal Financial

Gimbal Financial raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1,139.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,602 shares of the company’s stock after buying an additional 34,568 shares during the period. AbbVie comprises approximately 5.7% of Gimbal Financial’s investment portfolio, making the stock its 5th biggest position. Gimbal Financial’s holdings in AbbVie were worth $9,836,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. James T. Borello RIA raised its stake in AbbVie by 3.5% in the third quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock valued at $312,000 after buying an additional 40 shares during the last quarter. ACT Advisors LLC. grew its stake in shares of AbbVie by 2.5% during the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares during the last quarter. Willner & Heller LLC grew its stake in shares of AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares during the last quarter. B.O.S.S. Retirement Advisors LLC grew its stake in shares of AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after acquiring an additional 43 shares during the last quarter. Finally, Fielder Capital Group LLC increased its holdings in shares of AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after acquiring an additional 43 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 0.6%

Shares of ABBV stock traded down $1.72 during mid-day trading on Monday, reaching $283.70. The stock had a trading volume of 1,392,670 shares, compared to its average volume of 6,388,145. The business’s fifty day moving average is $262.74 and its 200-day moving average is $239.41. The firm has a market cap of $501.23 billion, a price-to-earnings ratio of 80.16, a PEG ratio of 1.30 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the business posted $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts forecast that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Guggenheim reaffirmed a “buy” rating and issued a $288.00 price objective on shares of AbbVie in a research report on Friday, October 9th. Wells Fargo & Company boosted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. UBS Group upped their price target on shares of AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research note on Tuesday, October 6th. Bank of America restated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Finally, Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.